Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava
Shionogi completed a $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding an approved ALS treatment to its portfolio. The deal transfers all intellectual property, sales rights and the existing commercial team, delivering an estimated $700 million in annual sales and becoming accretive in fiscal 2026. It also gives Shionogi an established U.S. rare‑disease infrastructure and the oral suspension formulation approved in 2022. The transaction supports Shionogi’s broader shift toward a best‑in‑class rare‑disease franchise.
Healthcare Affordability Requires a Collective Effort, Industry Leaders Say
At the ViVE health‑tech conference, HFMA‑led panelists warned that healthcare affordability is an urgent, collective challenge. A Gallup poll shows 29 % of Americans now view cost as the top concern, up from 23 % a year earlier. Providers plan to spend...
Women More Likely to Die From Cardiac Arrest because of Their Bras
Research by Thames Valley Air Ambulance and St John Ambulance shows that one in three women in the UK who suffer out‑of‑hospital cardiac arrest receive no CPR before emergency crews arrive. About 33% of men report hesitancy to perform chest compressions...
FDA Approves Eli Lilly’s Foundayo Pill as NHS Expands Wegovy to Over 1 Million Heart Patients
The FDA gave fast‑track approval to Eli Lilly’s oral GLP‑1 obesity drug Foundayo, and the UK’s NHS announced a rollout of semaglutide (Wegovy) to over 1 million adults with prior heart attacks or strokes. Both moves broaden the therapeutic reach of GLP‑1...
To Bend the Curve on Heart Disease, Prevention Must Move Upstream
Heart disease remains the leading cause of death in the United States, yet preventive cardiovascular screening is scarce and confined to specialist settings. Advanced imaging tools can detect risk early, but most primary care visits only include basic vitals, leaving...
Harvard Launches Trial to Test Psychedelic Coaching Boost for Ketamine Depression Therapy
Harvard investigators at Massachusetts General Hospital have started a randomized clinical trial to evaluate whether adding psychedelic coaching to FDA‑approved ketamine infusions improves outcomes for patients with treatment‑resistant depression. The study aims to settle a growing debate over the role...
UK NHS to Offer Wegovy to 1.2 Million Heart Patients, Expanding GLP‑1 Use Beyond Obesity
The UK’s National Health Service will prescribe semaglutide (Wegovy) to about 1.2 million adults who have had a heart attack or stroke and have a BMI of 27 or higher. The move follows NICE’s recommendation and a cost‑effective deal with Novo...
NUS Unveils Wearable Sensor that Tracks Fatigue and Stress with Clinical-Grade Accuracy
The National University of Singapore announced a wearable sensor that continuously monitors fatigue and stress, achieving 93% peak‑detection accuracy and ISO‑grade signal quality. The device, built on a metahydrogel platform with AI denoising, could give meditation practitioners a reliable physiological...
GE HealthCare Receives FDA Clearance for True Definition DL CT Image Reconstruction Technology
GE HealthCare has obtained FDA 510(k) clearance for its True Definition DL CT image reconstruction technology. The AI‑driven tool enhances spatial resolution in high‑contrast regions such as lungs, musculoskeletal tissue, and the inner ear, delivering ultra‑high‑resolution images in under one...
Why You Might Want to Hire Home Health Aides Through an Agency – Despite the Cost
Hiring home health aides through an agency costs more than direct hiring, but offers structured recruitment, wage transparency, and employee benefits. First Light Home Care in suburban Boston screens hundreds of candidates and hires only about 3%, paying caregivers $19‑$24...
Harbin Institute of Technology Demonstrates DNA Nanorobots that Capture SARS‑CoV‑2
Scientists from the Harbin Institute of Technology have built DNA‑based nanorobots that can locate and bind SARS‑CoV‑2 virus particles in vitro. The machines, only a few dozen nanometers across, use strand‑displacement chemistry to change shape and deliver drugs directly to...
First Human Trial Shows Fasting Mimic Boosts Autophagy
As a medical school professor, I teach that autophagy -- the body's cellular recycling system -- is one of the most powerful defenses against aging and disease. Now the first-ever human clinical trial proves a fasting mimicking diet activates it. Cedars-Sinai and...
The New Antitrust Era: Why CVS-Style Healthcare Integration Is Now the FTC’s Primary Target
The FTC and DOJ are overhauling antitrust review in healthcare, shifting focus from traditional market‑share and price analysis to how vertically integrated systems control patient flow. Updated Hart‑Scott‑Rodino filing rules now demand explanations of ecosystem design, strategic intent, and internal...
Rural America Doesn’t Need Another Framework … It Needs Care by September 2026
The CMS Rural Health Transformation Program will undergo its first performance review in September 2026, linking future funding to measurable patient outcomes. While policymakers debate long‑term frameworks, rural communities are already facing acute mental‑health bed shortages, with thousands forced into...
The Rollercoaster Ride Stopps and Danish IO Biotech Goes Bust
Copenhagen‑based IO Biotech, a cancer immunotherapy firm, saw its flagship melanoma vaccine Cylembio miss the primary endpoint in a Phase III trial, prompting the FDA to advise against filing for approval. The regulatory setback left the company with insufficient runway, as...
Merck Receives the EC Approval for Keytruda, Plus CT ± Avastin to Treat PD-L1+ Pt-Resistant Ovarian Carcinoma
The European Commission has granted approval for Merck’s Keytruda (pembrolizumab) combined with paclitaxel, with or without Avastin, to treat PD‑L1‑positive, platinum‑resistant ovarian, fallopian‑tube or primary peritoneal carcinoma. The indication covers adults who have received one or two prior systemic regimens...
Dental Implants in 2026: What Patients and Providers Need to Know
Dental implants have transitioned from a last‑resort option to the standard of care for single‑tooth replacement, driven by higher success rates and bone‑preserving benefits. Advances in cone‑beam imaging and guided‑surgery software now deliver pinpoint accuracy, shortening procedures and reducing complications....
I Double and Triple and Quadruple Down, because I Know What Victory Looks Like; Meet the “Journalists”
The blog post stages a fictional, off‑the‑record interview with a figure named Kennedy, who claims to be coordinating a campaign to erode confidence in vaccines and medical regulators. The dialogue suggests a long‑term strategy to “soften up” opposition, manipulate public...
Politics Should Not Determine Who Gets Admitted To Medical School
The Department of Justice, acting on a Trump administration executive order, has opened investigations into the admission practices of Ohio State University, Stanford University and UC San Diego medical schools, demanding seven years of applicant data and threatening loss of...
You’re Not Alone: Community Beats Solo Weight‑Loss Journey
Founder Diaries Day 2 - About feeling less alone. Community. Something I feel very strongly about while building MYRESET — treatment alone is not enough. Especially for weight loss. It can be quite scary… injections, side effects, all the unknowns. Yes, doctor support matters. But honestly,...
Fine Particulate Air Pollution Raises Alzheimer's Risk
As a medical school professor, I teach students that Alzheimer's has many risk factors. But this one is invisible -- and almost nobody talks about it. A massive study of 27.8 million Medicare beneficiaries just found that fine particle air pollution...
How Trump’s War in Iran Is Scrambling Pharma’s Shipping Options
U.S. and Israeli strikes on Iran have tightened the Strait of Hormuz blockade, cutting off a key east‑west artery that handles roughly 10% of global pharmaceutical shipments. Temperature‑controlled ingredients, which make up about 20% of those flows, are especially vulnerable,...
Wave 4 & 5 - ECR Health Care Complex / FAAB
Wave 4 and 5 of the ECR Health Care Complex in Sopot, Poland, are slated for completion in 2025, adding an analytical laboratory, outpatient clinic, day‑surgery hospital, and specialist hospital to the campus. The development reclaims five hectares of flood‑prone brownfield land...
Dominican National Pleads Guilty to Illegal Reentry, Misuse of Social Security Number, and Benefits Fraud
A Dominican national illegally residing in the United States pleaded guilty in Rhode Island federal court to a decade‑long scheme that used stolen identities to obtain roughly $75,000 in Medicaid, SNAP and unemployment benefits. Jesus Matos Perez admitted to illegal...
Marathon Health’s Newly Appointed CEO Looks to Maintain a Flexible Model
Marathon Health appointed Chris Pricco as chief executive officer, succeeding co‑founder Jeff Wells. Pricco said the company will keep its flexible advanced primary‑care (APC) model, tailoring on‑site or network clinics to each employer’s workforce. He highlighted three priorities: flexible service...
Restor3d Launches Aeros Modular Stem System
restor3d announced the full commercial launch of its Aeros Modular Stem System for total ankle replacement, becoming available in the United States on April 2, 2026. The system, part of the Kinos Total Ankle portfolio, features 3D‑printed porous tibial and...
Comprehensive Management of Shoulder Injuries Through Surgical Intervention and Specialist Care
Shoulder injuries, ranging from rotator cuff tears to frozen shoulder, demand a coordinated care pathway that begins with precise diagnosis and often starts with conservative therapy. When non‑surgical measures such as physical therapy and anti‑inflammatories fail, minimally invasive arthroscopic techniques...
Creatine Plus Probiotic Eases Depression via Gut‑brain Energy Boost
1/2) New placebo-controlled human randomized controlled trial finds creatine + a specific probiotic is effective in treating depression. The mechanism is fascinating, involving the probiotic increasing creatine transporters in the gut, leading to increased brain energy metabolism. If you're passionate about this...
Supporting Oral Health at Every Stage with Family Dentistry and Restorative Treatments
Maintaining oral health throughout life demands a proactive blend of preventive care and restorative treatments. Family dentists deliver continuity, offering routine exams, cleanings, fluoride applications, and early diagnosis for children, adults, and seniors. Modern restorative options—fillings, crowns, bridges, and especially...
Epic’s New Networks
Epic quietly announced two network‑based products that extend its electronic health record platform beyond traditional modules like Agent Factory or Penny. The new offerings focus on creating a shared data exchange layer, positioning Epic as a hub for interoperable health...
A New Implant Aims to Rewire the Brain to Help Stroke Patients
Epia Neuro, a San Francisco startup, unveiled a brain‑computer interface paired with a motorized glove to restore hand function in stroke patients. The disk‑shaped implant sits under the skull, captures neural intent from undamaged brain regions, and translates it via...
Biocytogen and Sihuan Pharmaceutical Partner to Discover Novel Therapeutics in Multiple Indications
Biocytogen and China’s Sihuan Pharmaceutical have signed a strategic partnership to co‑develop novel antibody therapeutics across several disease areas, including obesity. The deal merges Biocytogen’s fully human antibody discovery platform—featuring target‑humanized mouse models, in‑vivo efficacy systems, and an AI‑driven sequence...
Hospitals Overspend on Consultants and Supplies, Resist Savings
Why aren’t any of these at risk hospitals publishing their full accounting so everyone can see where they spend their money ? All but one group of hospitals that I have looked at potentially investing in, spend so much on consultants...
Sinclair Reverses Mouse Infertility, Challenges Menopause Limits
David Sinclair's lab just reversed infertility in mice that had been infertile for 6 months. They took 16-month-old mice, the equivalent of a woman well past menopause, and made them produce offspring again. The belief has always been that mammals run out...
ACC 2026: Meta-Analysis Supports CagriSema as Superior First-Line Therapy in Obesity
At the ACC 2026 meeting, a Bayesian network meta‑analysis of 2,803 overweight and obese adults showed that the fixed‑dose combination CagriSema outperformed its components, cagrilintide and semaglutide 2.4 mg, across all efficacy measures. CagriSema delivered the greatest absolute and percent weight...
Don't Let Trendy Peptides Replace Fundamental Patient Care
As a physician today, you are no longer just fighting Dr. Google. You are fighting an entire wellness culture that convinces patients a daily injection can outsmart chronic burnout and sleep deprivation. The modern patient encounter often begins with a specific...
Why Do Black Women Have Worse IVF Outcomes?
A University of Pennsylvania analysis of more than 246,000 IVF cycles found that Black women experience a live‑birth rate of about 45%, compared with roughly 60% for white women. Despite responding slightly better to ovarian‑stimulation drugs and producing high‑quality embryos,...
Over 90% Athletes Experience GI Issues After Concussion
Gastrointestinal symptoms after sport-related concussions 🧠💥 This new study conducted a survey of 106 athletes who retrospectively self-reported… 💥 Concussion history 😮💨 GI symptoms 💩 Bowel function Here is what they found ⬇️ 📝 90.6% reported ≥1 GI symptom post-concussion …with greater severity observed for appetite loss,...
Cyber-Physical Security Gaps Demand Attention, Health-ISAC’s 2025 Exercise Series Finds
Health‑ISAC’s 2025 resilience exercise series revealed persistent gaps in coordinating cyber and physical security teams across seven simulated ransomware‑plus‑intrusion tabletop drills. Participants repeatedly reported fragmented communication, delayed escalation, and insufficient joint response procedures. The after‑action report distilled twelve priority observations,...
Educate, Don't Convince: Respect Patient Autonomy in Surgery Decisions
Yesterday's post prompted a number of practitioner responses expressing frustration that "patients don't listen to them". Well.... that's okay. One of the hardest conversations in this profession is between the patient who wants something done and the surgeon who...
Trump Says War Spending Will Cut Medicare, Medicaid
And here’s a 30 second ad against every Republican in the country. Trump ran on protecting Medicare and Medicaid, he’s now explicit that Iran war spending means those programs must be cut.
Queensland Launches First Eating‑Disorder Recovery Village on Sunshine Coast
Mark and Gaye Forbes opened Queensland's inaugural recovery village for eating‑disorder survivors on the Sunshine Coast, backed by $1.9 million in state funding. The eight‑unit community offers short‑term, supported living for up to 60 families each year, signaling a new model...
23 Trends Shaping the Near Future of Medicine
23 trends that depict the near future of medicine and healthcare. Over 50,000 copies sold in 5 languages. A lot of figures, interviews and scenarios. This is "The Guide to the Future of Medicine". Check it out: https://t.co/1iBcCX2kfI https://t.co/gyfRu23Kt9
Rhythm Posts First FDA Approval for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) as the first therapy for acquired hypothalamic obesity, covering adults and children aged four and older. The decision follows the Phase 3 TRANSCEND trial, which demonstrated an 18.4% mean BMI reduction versus placebo...
1390. Your Doctor Is Wrong About Autism (Here’s How To Reverse It)
In the latest episode of The Human Upgrade, host Dave Asprey and integrative‑health practitioner Tracy Slepcevic argue that autism is a reversible biological condition driven by gut dysfunction, mitochondrial collapse, and toxic environmental exposures. They detail protocols—including gut healing, plasmalogen...
Closing the Gaps in Stroke Care: Access, Innovation and Global Equity
Linnea Burman, President of Medtronic Neurovascular, highlighted that nearly 12 million people suffer a stroke each year and one in four die within a year, underscoring persistent global gaps in prevention, access, and long‑term care. She emphasized that rapid treatment is...
AstraZeneca Reports the P-III (EMERALD-3) Trial Data on Imfinzi Combination + TACE in Unresectable Hepatocellular Carcinoma
AstraZeneca presented interim data from its Phase III EMERALD-3 trial, evaluating a single priming dose of Imjudo (300 mg) plus Imfinzi (1500 mg) followed by quarterly Imfinzi and transarterial chemoembolisation (TACE) with or without lenvatinib in 760 patients with unresectable hepatocellular carcinoma...
Case Western Study Finds NMN and NR May Shield Pancreatic Cancer Cells From Chemotherapy
Researchers at Case Western Reserve University reported that nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can help pancreatic cancer cells survive standard chemotherapy, raising safety concerns for patients and the biohacking community that widely uses these supplements.
Federal Trial in UnitedHealthcare CEO Murder Delayed to October
U.S. District Judge Margaret Garnett moved the federal trial of Luigi Mangione, accused of killing UnitedHealthcare CEO Brian Thompson, to October 2026. Jury selection will start Oct. 5 and opening statements Oct. 26, after rejecting the defense’s request to postpone the case...
FDA Grants Fast Track Approval to Eli Lilly's $149‑$349 Daily Weight‑Loss Pill Foundayo
The U.S. Food and Drug Administration has granted expedited approval to Eli Lilly's oral GLP‑1 weight‑loss pill, Foundayo, priced between $149 and $349 per month. The decision pits Lilly against Novo Nordisk’s injectable and oral options and could reshape obesity...